SERPINB4 antibody
- Known as:
- SERPINB4 (anti-)
- Catalog number:
- orb100538
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- SERPINB4 antibody
Related genes to: SERPINB4 antibody
- Gene:
- SERPINB4 NIH gene
- Name:
- serpin family B member 4
- Previous symbol:
- SCCA2
- Synonyms:
- PI11, LEUPIN, SCCA-2, SCCA1
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-09-15
- Date modifiied:
- 2016-04-06
Related products to: SERPINB4 antibody
Related articles to: SERPINB4 antibody
- Psoriasis is a chronic inflammatory autoimmune skin disease for which no standardised and reliable molecular biomarkers of disease course or activity are currently available. Here, we aimed to identify serum biomarkers of psoriasis. Serum samples from 40 patients with psoriasis and 40 healthy volunteers were analysed using ELISA and Proximity Extension Assay proteomics. ELISA revealed significantly increased serum levels of AGO2 and APOA1 in psoriatic patients versus controls, with a strong association between APOA1 and psoriasis (OR = 20.72, 95% CI of 4.57-93.87, = 0.000137). Targeted serum proteomics additionally identified 35 differentially expressed proteins, including well-known psoriasis drivers (e.g., top upregulated IL17A and SERPINB4). The most downregulated was adrenomedullin (ADM, FC = -10.12). For 14 altered proteins, no previous direct associations with psoriasis were reported. Among them, DEFB103A_DEFB103B and DSG3 showed the best discrimination between psoriasis and control samples, while SERPINB4 correlated with psoriasis severity. APOA1, DEFB103A_DEFB103B, and DSG3 emerge as novel candidate circulating psoriasis biomarkers, and SERPINB4 as a biomarker of psoriasis severity. The functional role of DSG3 and other newly identified proteins (ACRV1, HAO1, ADH4, GPD1, GFER, PTGES2, DSG3, AFAP1L1, GALNT3, RASGRP2, MAP2K6, LXN, NBEAL2, and VPS54) in psoriasis requires further studies. - Source: PubMed
Publication date: 2026/06/26
Dźwigała MonikaSys DorotaŻycka-Krzesińska JoannaRybicka BeataPopławski PiotrWalecka-Herniczek IrenaPiekiełko-Witkowska AgnieszkaBogusławska Joanna - Atopic dermatitis (AD) is a common chronic inflammatory skin disease with heterogeneous and poorly understood mechanisms. We perform single-cell RNA sequencing of lesional (LAD) and non-lesional (NAD) skin from 42 AD patients and 23 healthy controls (HC). Keratinocytes (KCs) are the predominant disease-relevant cell type. In healthy skin, KC differentiation follows a linear trajectory from basal KCs through seven differentiated stages to terminal keratinized cells. In LAD, this process is disrupted, showing a reversed terminal transition mainly driven by DK7 cells. APOD, LYZ and SERPINB4 emerge as LAD-specific regulators linked to IL-13/IL-22 responses, ER stress and oxidative damage. Mitochondrial and ER dysfunction are specifically enriched in LAD DK6 cells, indicating a key pathogenic compartment. Spatial transcriptomics and cell-cell interaction analysis further identify LAD-specific TWEAK signaling from IL-13 Th2/cycling T cells to Fn14 basal/differentiated KCs. Here, we reveal disrupted KC differentiation and immune signaling circuits in AD, highlighting potential therapeutic targets. - Source: PubMed
Publication date: 2026/07/14
Qin TingtingBogle RachaelJiang RundongSarkar Mrinal KCai YuliGharaee-Kermani MehrnazFox JenniferXing XianyingMarella SahitiNakamura MioMaverakis EmanualLe Stephanie TMerleev Alexander AMarusina Alina ISimpson Cory LParihar ArtiHill ConnorLi HeKahlenberg J MichelleWaterworth Dawn MSabins NinaMiller Lloyd SFreeman Tom CLeung Monica WlPolak Marta ETsoi Lam CBilli Allison CGudjonsson Johann E - Squamous cell carcinoma antigen (SCC-Ag) and carcinoembryonic antigen (CEA) are routinely monitored after definitive chemoradiotherapy (dCRT) for esophageal squamous cell carcinoma (ESCC) in Japan, but their clinical significance remains unclear. - Source: PubMed
Sakanaka KatsuyukiKato KenMachida RyunosukeIto YoshinoriDaiko HiroyukiKajiwara TakeshiTsubosa YasuhiroMinashi KeikoAbe TetsuyaKojima TakashiHara HirokiKawakubo HirofumiTsunoda ShigeruWatanabe MasayaDoki YuichiroNagatani YoshiakiKimura YasueSasaki KeitaTakeuchi HiroyaKitagawa Yuko - Lymph node metastasis (LNM) is an important prognostic factor of cervical cancer, significantly impacting patient outcomes and treatment strategies. Current methods for predicting LNM after surgery are limited, necessitating the identification of reliable biomarkers. This study aimed to evaluate the diagnostic value of serum squamous cell carcinoma antigen (SCC-Ag) combined with cytokeratin fragment 21-1 (CYFRA 21-1) for identifying long-term LNM after cervical cancer surgery. - Source: PubMed
Xu KaizhenZhang Guilan - To identify predictive biomarkers for immunotherapy response in advanced/recurrent cervical cancer by evaluating peripheral blood indicators including T-cell subsets and serum biomarkers. This prospective study (June 2022-July 2024) enrolled 50 patients with stage III-IVa or recurrent cervical cancer receiving first-line immunotherapy combined with chemo/radiotherapy from Qingdao Central Hospital network. We analyzed baseline CD4/CD8 T-cell percentages and post-treatment (after one course) levels of CA125, SCCA, T-cell subsets, and PD-1 expression on T-cells using logistic regression (treatment efficacy，comparing 36 responders vs. 14 non-responders) and Cox regression (prognosis, with disease progression or death events occurring in 26 patients). Treatment response was significantly associated with: (1) baseline CD4 T-cell percentage and (2) post-treatment CA125/SCCA levels, CD8 T-cell percentage, and PD-1 expression on both CD4+/CD8+ T-cells (all < .05). Prognostic factors identified by Cox regression included these same markers plus post-treatment CD4 T-cell percentage. Optimal responders showed: high baseline CD4 T-cells, low post-treatment CA125/SCCA, elevated CD4/CD8 T-cells, and reduced PD-1 expression. Peripheral T-cell subsets and serum biomarkers show significant associations with predicted immunotherapy outcomes. High baseline CD4 T-cells with post-treatment normalization of immune markers (increased T-cells, decreased PD-1+ cells, and tumor antigens) are associated with a higher likelihood of benefiting from immunotherapy. It should be noted that this study has limitations, including a modest sample size and the assessment of biomarkers at only a single post-treatment time point, which may affect the generalizability of the findings. These peripheral blood biomarkers may represent a minimally invasive approach for exploring treatment dynamics and are considered worthy of further investigation as potential adjuncts in the context of personalized immunotherapy for advanced cervical cancer. However, their predictive performance and clinical utility remain to be validated in larger, independent cohorts before any clinical application can be considered. - Source: PubMed
Publication date: 2026/06/23
Bai JingCui Xiao-LiBo Si-JiaSun Li